MedTrace Logo

The Effect of Sodium Zirconium Cyclosilicate on Albuminuria in Patients With Type 2 Diabetes and Hyperkalemia

NCT04063930 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-10-16

No results posted yet for this study

Summary

To investigate whether concomitant treatment with Lokelma can improve the efficacy of standard blockade of the renin-angiotensin system in patients with type 2 diabetes, diabetic nephropathy and hyperkalemia.

Conditions

  • Type 2 Diabetes Mellitus With Kidney Complications

Interventions

DRUG

LOKELMA 5 GM Powder for Oral Suspension

Sodium zirconium cyclosilicate (a hyperkalemia treatment)

DRUG

Placebos

Matching placebo

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Zealand University Hospital

    collaborator OTHER

  • Steno Diabetes Center Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-31
Primary Completion
2020-12-31
Completion
2021-12-31
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04063930 on ClinicalTrials.gov